Notably, the antitumor activity of ASAH1 inhibitors has surpassed that of temozolomide (TMZ)—an FDA-approved chemotherapeutic—suggesting that pharmacological inhibition of ASAH1 may increase ceramide accumulation in tumor tissue and induce apoptosis in glioma cells [68,69]. The gene discussed is ASAH1; the disease is central nervous system cancer.